- Home
- SKYA vs FLNA Comparison
SKYA vs FLNA Comparison
Compare SKYA & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYA | FLNA |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.0M | 61.8M |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SKYA | FLNA |
|---|---|---|
| Price | $0.99 | $0.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 157.9K | ★ 314.7K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $204,120.00 | ★ $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $0.86 |
| 52 Week High | $1.54 | $2.03 |
Technical Indicators
Market Signals| Indicator | SKYA | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 35.01 | 32.78 |
| Support Level | $0.91 | $0.86 |
| Resistance Level | $1.26 | $1.05 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 2.94 | 8.30 |
Price Performance
Historical ComparisonAbout SKYA SkyAI Inc. Common Stock
SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.